Pharma BD Deal Intelligence
Nestlé's $11.85B carve-out of Pfizer Nutrition bought China formula share at a premium, but the acquired Wyeth/S-26 brands lost ground to local rival Feihe and China's collapsing birth rate gutted demand—forcing a 2023 plant closure and €472M restructuring charge a decade later.
Credit Suisse's Alex Molloy: 'They may face anti-trust troubles that may force them to sell parts of the business' — flagged ~25% of Pfizer Nutrition revenue…
Chinese MOFCOM approval came with conditions, clearing the final major regulatory hurdle and validating Nestle's emerging-market thesis behind the…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Nestle acquired Pfizer Nutrition (infant formula carve-out from Wyeth heritage) for $11.85B cash. Strengthened Nestle position in emerging-market infant nutrition (especially China). Note: borderline consumer-health categorization; included given carve-out from a top-15 pharma.
Assessment window: 5yr post-close.
$41.0B Global infant formula market ~$41B (2012-2013); China ~23% share
Infant formula is a regulated nutritional product, not a disease treatment, used as breast-milk substitute or supplement for infants 0-12 months. Premium tiers and stage-graded formulas are tightly tied to maternal income, urbanization and middle-class formation in emerging markets — making the category a consumer-staples growth play rather than a pharmaceutical one.
Pre-deal, the global infant formula market (~$41B) was an oligopoly: Danone (Nutricia/Aptamil/Nutrilon), Mead Johnson (Enfamil), Nestle (NAN/Lactogen/Gerber), Abbott (Similac) and Pfizer Nutrition (Wyeth heritage: S-26 Gold, SMA, Promil) controlled the bulk of premium tiers. Pfizer's franchise — inherited from the 2009 Wyeth acquisition — was disproportionately concentrated in China and other Asian emerging markets, where Wyeth's S-26 Gold commanded super-premium positioning. By outbidding Danone, Nestle bought roughly 85% overlap with its growth strategy in China while triggering antitrust review in markets like Mexico and Australia where Credit Suisse's Alex Molloy estimated ~25% of the unit's revenue could be at risk for forced divestiture. The deal closed Nov 30, 2012 at a 19.8x EBITDA multiple analysts called full but defensible given Nestle's #1 global position lock-in.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Nestle SA / Pfizer Nutrition (Pfizer Inc. infant nutrition unit) (this deal) | 2012 | $11.8B | 50 |
| Nestle SA / Novartis Medical Nutrition | 2006 | $2.5B | 64 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
← Browse all deals · How we score deals
More: 2012 deals · Other deals